Zobrazeno 1 - 10
of 62
pro vyhledávání: '"A. W. Unzeitig"'
Autor:
Yanin Chavarri-Guerra, Ana Ferrigno-Guajardo, Cynthia Villarreal-Garza, Bertha Alejandra Martinez-Cannon, Julio Abugattas-Saba, Annette C. Fontaine, Darling J. Horcasitas, Pamela Mora-Alferez, Gary W. Unzeitig, Sandra Brown, Alejandro Mohar-Betancourt, Bita Nehoray, Azucena Del Toro-Valero, Adrian Daneri-Navarro, Pamela Ganschow, Ian Komenaka, Yenni Rodriguez, Gubidxa Gutierrez Seymour, Leonora Valdez, Kathleen R. Blazer, Shellie Ellis, Jeffrey N. Weitzel
Publikováno v:
JCO Global Oncology, Iss 10 (2024)
PURPOSEWomen with pathogenic variants (PVs) in breast cancer (BC) and ovarian cancer (OC) associated genes are candidates for cancer risk-reducing strategies. Limited information is available regarding risk-reducing surgeries (RRS) among Hispanics. T
Externí odkaz:
https://doaj.org/article/1f55e679c5e74ea8ab1ce642911bc1f3
Autor:
Jeffrey N. Weitzel, Yanin Chavarri-Guerra, Ana Ferrigno, Pamela Mora-Alférez, Annette Campbell-Fontaine, Cynthia Villarreal-Garza, Alejandro Mohar-Betancourt, Gubidxa Gutierrez-Seymour, Gary W. Unzeitig, Sandra Brown, Bita Nehoray, Azucena del Toro-Valero, Pamela Ganschow, Ian Komenaka, Yenni Rodriguez, Francisco Gutierrez-Delgado, Kathleen R. Blazer
Publikováno v:
Cancer Research. 82:2214-2214
Background: Patients at increased risk of breast (BC) and/or ovarian (OC) cancer can opt for risk-reducing surgeries (RRS). However, there are disparities in access to genomic cancer risk assessment (GCRA) and cancer prevention interventions related
Autor:
Matthew J. Ellis, Meenakshi Anurag, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard Gibbs, Souzan Sanati, Kiran Vij, Mark Watson, Travis Dockter, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erica Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, A. Marilyn Leitch, Gary W. Unzeitig, Eric Winer, Anna Weiss, Kelly Hunt, Ann H. Partridge, Charles M. Perou, Vera Suman, Cynthia X. Ma, Lisa A. Carey
Publikováno v:
Cancer Research. 82:CT026-CT026
Introduction: The ALTERNATE trial randomized postmenopausal women with ER Allred 6-8 HER2- breast cancer to 6 months of NET with anastrozole (A), fulvestrant (F) or the combination (A+F). Biopsies were taken preNET and after 4-weeks(wks). Patients wi
Autor:
Cynthia X Ma, Meenakshi Anurag, Travis Dockter, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard Gibbs, Souzan Sanati, Kiran Vij, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J Hieken, Yang Wang, A. Marilyn Leitch, Gary W Unzeitig, Anna Weiss, Eric P Winer, Kelly Hunt, Ann H Partridge, Lisa A Carey, Charles M Perou, Matthew J Ellis, Vera Suman
Publikováno v:
Cancer Research. 82:PD9-03
Background: Neoadjuvant ET (NET) offers an opportunity to assess ET sensitivity for ER+ HER2- BC and potentially to tailor therapy. Ki67 >10% on biopsy after 2-4 weeks (wks) of NET identifies patients (pts) with intrinsic ET resistance; while patholo
Publikováno v:
Annals of Vascular Surgery. 77:327
Autor:
Katia Fernandez, Griselda Rubio, Electra D. Paskett, Jessica L. Krok-Schoen, Douglas M. Post, Gary W. Unzeitig
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 27(2)
Patient-clinician communication difficulties are a major barrier to effective symptom management during chemotherapy especially among non-English-speaking and minority patients. This study sought to examine how information is exchanged between patien
Autor:
Ogheneruona, Apoe, Sin-Ho, Jung, Heshan, Liu, Drew K, Seisler, Jayne, Charlamb, Patricia, Zekan, Lili X, Wang, Gary W, Unzeitig, Judy, Garber, James, Marshall, Marie, Wood
Publikováno v:
American journal of hematology/oncology. 12(7)
One in eight women will develop breast cancer over their lifetime with 230,000 women diagnosed in 2015. For this reason, breast cancer prevention efforts are essential. Vitamin D, with anticancer properties, may have a role in prevention of some canc
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 309(2)
The discriminative stimulus effects of gamma-hydroxybutyrate (GHB) can be mimicked by GABA(A) receptor-positive modulators (e.g., diazepam) and GABA(B) receptor agonists (e.g., baclofen). The purposes of this study were to see whether stimulus contro
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics; May 2004, Vol. 309 Issue: 2 p540-7, 8p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.